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Background: CDK4 is a protein kinase in the CDK family important for G1/S phase cell cycle progression. However,
the roles and molecular mechanisms of CDK4 triggering nasopharynx carcinogenesis are still unclear.
Methods: Lentiviral-vector mediated shRNA was used to suppress CDK4 expression and examine its molecular
mechanisms. Using immunohistochemistry, we analyzed CDK4 protein expression in clinicopathologically
characterized nasopharyngeal carcinoma (NPC) cases and nasopharyngeal tissues (NPs). Survival curves were plotted
by the Kaplan-Meier method and compared using the log-rank test.
Results: In this investigation, we knocked down CDK4 expression and observed that NPC cell growth and cell
cycle progression were significantly blocked by suppressing expression of CCND1, CDK6, and E2F1 as well as
elevated p21 expression. Further, we found that reduced CDK4 expression elevated the expression of let-7c, a
tumor-suppressive miRNA modulated by E2F1. We found that let-7c was markedly downregulated in NPC tissues
compared to NPs and suppressed cell growth and cell cycle progression by modulating p15/p16/CDK4/E2F1
pathway. Finally, CDK4 protein was observed to be overexpressed in NPC tissues and could be considered an
unfavorable prognosis factor for NPC patients although its independent prognostic value did not reach statistical
significance (p = 0.087).
Conclusions: Our results demonstrated that overexpressed CDK4 is an unfavorable prognostic factor which
suppresses the expression of tumor suppressive-factor let-7c through p21/CCND1/CDK6/E2F1 signaling, and inhibits
cell proliferation by p15/p16/CDK4/E2F1 feedback signaling in NPC.
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NPC is one of the most common carcinomas in Southern
China and exhibits a highly malignant phenotype. Clinic-
ally, NPC is classified as a specific type of head and neck
squamous cell carcinoma with its unique epidemiology,
clinical characteristics, etiology, and histopathology. There-
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reproduction in any medium, provided the orunderlying molecular mechanisms of carcinogenesis. Syn-
ergetic effects of viral infections, genetic alterations, and
environmental factors are key factors driving the aberrant
activity of a variety of genes and signal pathways during
NPC pathogenesis. Epstein-Barr virus-encoded LMP1 pro-
motes proliferation and transformation of human nasopha-
ryngeal epithelial cells by inhibiting LKB1-AMPK pathway
[1]. A single nucleotide polymorphism -32G/A in the pro-
moter region of LOC344967 gene creates an activator
protein (AP-1)-binding site in its transcriptional regulatory
region, which significantly enhanced the binding of AP-1
to the promoter region of LOC344967 and activated its
expression in vivo [2]. Tobacco smoking as a risk factor
for NPC has been supported by multiple studies [3,4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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duced the expression of the immediate-early transcrip-
tional activators Zta and Rta, and increased transcriptional
expression levels of BFRF3 and gp350 in the lytic phase [3].
CDK4 is a member of the cyclin-dependent kinase
family and highly similar to the gene products of S. cere-
visiae cdc28 and S. pombe cdc2. It is a catalytic subunit
of the protein kinase complex including CDK4, CDK6,
and CCND1 important for G1 to S cell cycle progression.
CDK4 was observed to have higher oncogenic activity
than oncogenic transcript factor CCND1 and it markedly
enhanced malignant skin tumorigenesis in CDK4 trans-
genic mice [5]. Furthermore, overexpression of CDK4 has
been observed in many tumor types, including oral squa-
mous cell carcinoma [6], pancreatic endocrine tumors [7],
lung cancer [8,9], and nasopharyngeal carcinoma [10],
suggesting that CDK4 is a significant factor in promoting
the initiation and development of tumors. However, the
role of CDK4 and its mediated miRNA expression in the
pathogenesis of NPC have not been reported. In this
study, we found that knocking down CDK4 expression
elevated the expression of tumor suppressor let-7c by
modulating the G1/S transition cell signaling pathway,
which in turn suppressed cell growth by through the p15/
p16/CDK4/E2F1 pathway. Furthermore, overexpression of
CDK4 was considered an unfavorable factor associated
with NPC progression and poor prognosis.
Methods
Sample collection and cell culture
Cell culture and sample collection. Two NPC cell lines
5-8F and 6-10B were obtained from Cancer Research
Institute of Southern Medical University and maintained
in RPMI 1640 medium supplemented with 10% newborn
calf serum (NBCS) (PAA Laboratories, Inc, Pasching,
Austria) in a humidified chamber with 5% CO2 at 37°C.
133 paraffin-embedded undifferentiated NPC specimens
with clinical prognosis information and 34 paraffin-
embedded nasopharynx specimens (Table 1) were ob-
tained at the time of diagnosis before any therapy from
People’s Hospital in Zhongshan City (Guangdong, China).
Among 133 patients, there were 17 patients treated by
radiotherapy alone, 3 by chemocherapy, 105 by combine




Expression level NPs NPCs P = 0.001
Low 26 58
High 8 75
Total 34 133patients who did not accept any treatment. All 56 fresh
NPC and 15 NP samples (13 cases for chronic nasophar-
yngitis tissuses and 2 cases for normal nasopharyngeal tis-
sues) were obtained from an otorhinolaryngologist using
nasal endoscope. Subsequently, all samples were imme-
diately stored in liquid nitrogen. The clinical processes
were approved by the Ethics Committees of People’s
Hospital of Zhongshan City and patients gave informed
written consent. The pathologic stage of all specimens
was confirmed according to the 1997 NPC staging
system of the UICC.
RNA isolation, reverse transcription, and qRT-PCR
RNA was extracted from the NPC cell lines, NPC tissues
and normal nasopharynx tissues using Trizol (Takara,
Shiga, Japan). For miR-let-7c qRT-PCR expression analysis,
mature miRNAs were reverse-transcribed, and real-time
PCR was performed using All-in-One™ miRNA qRT-PCR
Detection Kit following the manufacturer’s protocol.
(GeneCopoeia™, Cat.No: AOMD-Q020). All data were
normalized to U6 expression. Assays were performed in
accordance with manufacturer’s instructions (Takara,
Shiga, Japan). PCR reactions for each gene were repeated
three times. miRNA expression was normalized to U6 ac-
cording to the following calculations: 1) First, calculating
Delta C(T) value of each sample (Targeted gene Ct
value-Housekeeping gene Ct value); 2) Second, calculat-
ing -Delta Delta C(T) value of each sample (each sample
Delta C(T) value -the maximal Delta C(T) value of all
sample Delta C(T) values; 3) Third, the expression level
of each sample was transformed to fold-relative value
including that sample with maximal Delta C(T) value by
2(-Delta Delta C(T)) method [11]. 4) Finally, the differ-
ential expression level was analyzed between objective
group and control group by t test.
Immunohistochemistry and evaluation of staining
Immunohistochemistry and evaluation of staining of
CDK4 (Santa Cruz Biotechnology, Santa Cruz, USA)
were performed in NPC and NP tissues according to the
previous description [12].
Western blot analysis
Western blot was carried out according to the previous
description [13,14] with rabbit polyclonal anti-CDK4
antibody, anti-ACTB, p21, E2F1, C-Myc antibody (1:400;
Santa Cruz Biotechnology, Santa Cruz, USA); p15 and
p16 antibody (Cell signaling technology, Danvers, USA),
CCND1 antibody (1:500; Epitomics, Burlingame, USA).
An HRP-conjugated anti-rabbit IgG antibody was used
as the secondary antibody (Zhongshan, Beijing, China).
Signals were detected using enhanced chemiluminescence
reagents (Pierce, Rockford, IL).
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of CDK4 short hairpin RNA
The preparation of lentivirus expressing human CDK4
short hairpin RNA (shRNA-509,1097) was reported by
us using the pLVTHM-GFP lentiviral RNAi expression
system [12]. NPC 5-8F cells were infected with lentiviral
particles containing specific or negative control vectors,
and polyclonal cells with GFP signal were selected for
further experiments using FACS flow cytometery.
Transient transfection with let-7c mimics and its inhibitor
Let-7c and its inhibitor were designed and synthesized
by Guangzhou RiboBio (RiboBio Inc, China). Twenty-four
hours prior to transfection, NPC cells 6-10B and 5-8F
were plated onto a 6-well plate or a 96-well plate (Nest,
Biotech, China) at 30–50% confluence. They were then
transfected into cells using TurboFectTM siRNA Trans-
fection Reagent (Fermentas, Vilnius, Lithuania) according
to the manufacturer's protocol. Cells were collected after
48-72 hr for further experiments.
Cell proliferation analysis
Cell proliferation was analyzed using MTT assay as de-
scribed previously [13]. For shRNA-CDK4, the cells were
incubated for 1, 2, 3, 4, 5, 6, or 7 d. For let-7c mimics or
its inhibitor, the cells were incubated for 1, 2, or 3d.
Colony formation assay
Cells were plated in 6-well culture plates at 100 cells/
well. Each cell group had 2 wells. After incubation for 12Figure 1 Stably knocking down CDK4 expression suppresses cell prol
protein expression was stably suppressed by lentivirus-mediated shRNA in
CDK4-suppressed cells compared to PLV-Ctr cells by MTT assay. C. In vitro p
CDK4-suppressed cells compared to PLV-Ctr cells by colony formation assa
transition from G1 to S in shRNA-CDK4-2 and 3 cells. Data are presented asdays at 37°C, cells were washed twice with PBS and
stained with Giemsa solution. The number of colonies
containing ≥ 50 cells was counted under a microscope.
The colony formation efficiency was calculated as (num-
ber of colonies/number of cells inoculated) × 100%.Cell cycle assay
To evaluate cell cycle distributions, cells were fixed in 70%
ice-cold ethanol for 48 hours at 4°C, and stained by incu-
bating cells with PBS containing 10 μg/mL propidium iod-
ide and 0.5 mg/mL RNase A for 15 min at 37°C, and
analyzed for the DNA content of labeled cells by FACS
Caliber Cytometry (BD Bioscience, USA). Each experi-
ment was done in triplicate.Statistical analysis
All data were analyzed for statistical significance using
SPSS 13.0 software. The Chi-square test was applied to
the examination of the differences of CDK4 expression
between normal epithelium and cancer tissues of naso-
pharynx as well as the relationship between CDK4 expres-
sion levels and clinicopathologic characteristics. Survival
analysis was performed using Kaplan-Meier method. Two-
tailed Student's t test was used for comparisons of two
independent groups. One-way ANOVA was used to
determine the differences between groups for all in vitro
analyses. A P value of less than 0.05 was considered
statistically significant.iferation and cell cycle progression in vitro in NPC. A. CDK4
NPC cells. B. In vitro viability of NPC cells was decreased in
roliferative ability of NPC cells was significantly decreased in
y. D. Stably downregulated CDK4 expression blocked cell cycle
mean ± SD for three independent experiments (*p < 0.05).
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Stably downregulated CDK4 expression suppresses cell
proliferation and cell cycle progression in vitro in NPC
In previous study, we demonstrated that suppressing
CDK4 expression using lentiviral-mediated shRNA inhib-
ited cell proliferation and G1 to S cell cycle transition. In
this study, we used lentiviral-mediated shRNA specifically
targeting CDK4 to stably inhibit expression of CDK4 in
the 5-8F cell line. Two single clone cells shRNA2 and
shRNA3 with stable suppression of CDK4 protein com-
pared to mock vector and 5-8F cell lines were identified
(Figure 1A). Subsequently, we observed that cell prolif-
eration ability was significantly reduced in comparison
to Mock cells by MTT (Figure 1B) and plated clone ana-
lysis (Figure 1C). Further, we found that knocking down
CDK4 expression delayed the transition of cell cycle
from G1 to S phase. These results suggested a signifi-
cant proliferative effect of CDK4 on tumorigenesis
in vitro (Figure 1D).Knocking down CDK4 elevates the expression of let-7c by
modulating G1/S cell cycle signal in NPC
Let-7c is a tumor-suppressive miRNA identified in some
tumors [15,16]. In this study, we used qPCR to examine
let-7c expression after knocking down CDK4 NPC cells.
Interestingly, let-7c expression was markedly upregu-
lated after suppressing CDK4 expression (Figure 2A).
CDK4 is not a transcription factor and it was unlikely to
directly control the expression of let-7c. However, based
on predicted binding sites of E2F1 in let-7c promoter,
we suspected that reduced CDK4 mediated the eleva-
tion of let-7c through suppression of E2F1 cell cycle
signaling. We observed that knocking down expression
of CDK4 decreased expression of CCND1, CDK6, and
E2F1 yet upregulated p21 (Figure 2B). Suppressing E2F1
expression by siRNA stimulated let-7c expression in
NPC 5-8F and 6-10B cells (Figure 2C,D). Our results
revealed that knocking down CDK4 elevated the expres-
sion of let-7c by modulating G1/S cell cycle signaling in
NPC.Figure 2 Repression of CDK4 elevates expression of let-7c by
modulating G1/S cell cycle signaling in NPC. A. Let-7c expression
was significantly increased in NPC cells after stable knockown of
CDK4 expression. B. Knocking down the expression of CDK4
decreased the CCND1, CDK6, and E2F1 as well as activated p21
expression. C. E2F1 expression was markedly suppressed using
specific siRNA-E2F1. D. Knocking down E2F1 by specific siRNA-E2F1
elevated the expression of let-7c.Let-7c is downregulated in NPC
Downregulated expression of let-7c has been confirmed
in some tumors [15,17]. However, its expression pattern
has still not been examined in NPC. In this study, we ex-
amined the differential expression of let-7c between 56
fresh NPC tissues and 15 fresh nasopharyngeal tissues
but not formalin-fixed, paraffin-embedded (FFPE) tis-
sues. The results showed that let-7c was significantly
reduced in NPC tissues compared to nasopharyngeal
tissues (Figure 3A), suggesting that let-7c might play a
suppressive role in NPC pathogenesis.
Figure 3 Let-7c is downregulated and suppressed cell growth and cell cycle progression. A. Compared to NP tissues, let-7c expression
was reduced in NPC tissues. B. Let-7c mimics or its inhibitor respectively suppressed or promoted cell growth. C. Let-7c mimics or its inhibitor
respectively suppressed or promoted G1 to S phase cell cycle progression.
Liu et al. BMC Cancer 2014, 14:274 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/274Let-7c suppresses cell proliferation and cell cycle
progression in NPC
To investigate the effect of let-7c, we introduced let-7c
mimics or its inhibitor respectively into NPC 5-8F and
6-10B cells. Compared with their negative controls, we
found that let-7c mimics or its inhibitor respectively
inhibited or promoted cell growth and cell cycle pro-
gression in NPC cells by MTT and Cytometry assays
(Figure 3B,C). Our results demonstrated that let-7c is a
potential tumor suppressor in NPC.
Let-7c modulates p15/p16/CDK4/E2F1 in NPC
In a previous investigation, let-7c was reported to directly
target C-Myc, thereby suppressing cell growth [18]. In this
study, we found that let-7c mimics elevated p15 and p16
expression and decreased the expression of CDK4 and
E2F1 in NPC 5-8F cells. Contrary to the specific effect
caused by the introduction of let-7c mimics, we observed
that the expression of p15 and p16 was inhibited and theexpression of CDK4 and E2F1 was enhanced by using
let-7c inhibitor in NPC 6-10B cells (Figure 4).
Overexpression of CDK4 is associated with NPC
progression and poor prognosis
Overexpression of CDK4 has been reported in NPC,
however, the correlation of CDK4 expression with clin-
ical features and prognosis of NPC has not been
documented. In this study, specific CDK4 protein stain-
ing was found in the cytoplasm and nucleus of normal
and malignant nasopharyngeal tissues by immuno-
histochemistry (Figure 5A). CDK4 protein was highly
expressed in NPCs compared to NP tissues (p = 0.001)
(Table 1). Furthermore, we observed that overexpressed
CDK4 was positively associated with tumor clinical
stage (I-II vs. III-IV) (p = 0.047), but not correlated with
patient's age, sex, smoking, lymph node metastasis
(N classification), tumor size (T classification), and distant
metastasis (M classification) in NPC (Table 2). Further,
Figure 4 Let-7c modulates cell cycle signaling. Let-7c mimics
elevated p15 and p16 expression and decreased and the expression
of CDK4 and E2F1 while its inhibitor had the opposite effect.
Table 2 Correlation between the clinicopathologic
characteristics and expression of CDK4 protein in NPC
Characteristics n CDK4 (%) P
Low expression High expression
Gender
Male 92 41 51
Female 41 17 24 0.850
Age(y)
≥50 67 29 38
<66 66 29 37 1.000
Smoking
No 111 50 61
Yes 22 8 14 0.490
T classification
T1-T2 99 41 58
T3-T4 34 17 17 0.426
N classification
N0-N1 74 30 44
N2-N3 59 28 31 0.483
Distant metastasis
Yes 10 3 7
No 123 55 68 0.512
TNM Clinical stage
I~II 50 16 34
III~IV 83 42 41 0.047
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sion for NPC patients and observed that the level of
CDK4 protein expression had significantly correlated
with overall survival (Figure 1F). Patients with higher
levels of CDK4 expression had poorer survival rates than
those with lower levels of CDK4 expression (Figure 5B).Figure 5 Overexpressed CDK4 and non-treatment of radiotherapy are associated with poor prognosis of NPC. A. CDK4 was expressed in
NPC and NP tissues. a,b, and c: Weak cytoplasmic expression of CDK4 in NP tissues. d: High cytoplasmic expression of CDK4 in NP tissue. e: High
cytoplasmic expression of CDK4 in NPC tissues. f and g: High cytoplasmic expression but low nuclear expression of CDK4 in NPC tissues. h: High
cytoplasmic and nuclear coexpression of CDK4 in NPC tissues. B. Overexpressed CDK4 was associated with poor prognosis of NPC.
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classifications and clinical stages were also significantly
correlated with patients’ survival (P = 0.002, P<0.001,
P = 0.002, P<0.001, and P<0.001 respectively). NPC pa-
tients with the treatment of radiotherapy had markedly bet-
ter overall survival rates than those without the treatment
of radiotherapy (p = 0.001).We performed multivariate ana-
lysis of CDK4 protein expression levels adjusted for all
factors and found that the level of CDK4 expression indi-
cated a tendency as an independent prognostic factor for
NPC (P = 0.087) (Table 3).
Discussion
Dysfunction of cell cycle signaling is one of main features
in NP carcinogenesis [10,19]. CDK4, a member of the
cyclin-dependent kinase family, is a key factor of cell cycle
signal affecting cell cycle progression and its overexpres-
sion has been described in many tumors, including NPC.
However, CDK4-mediated molecular mechanisms linked
to the initiation and development of NPC are not com-
pletely understood.
In previous studies, CDK4 had been shown to promote
cell proliferation by driving cell cycle progression [20-26].




Male vs. female 0.583 1.176
Age
≥50vs. <50 years 0.352 1.281
Family tumor history
Yes vs. No 0.970 1.022
Smoking
Yes vs. No 0.979 1.010
Chemotherapy
Yes vs. No 0.585 1.220
Radiotherapy
Yes vs. No 0.002 0.308
T classification
T1-T2 vs. T3-T4 0.000 2.611
N classification
N0-N1 vs. N2–N3 0.002 2.317
M classification
M0 vs. M1 0.000 7.280
Clinical stage
I-II vs. III-IV 0.000 5.222
Expression of CDK4
High expression vs. low expression 0.099 1.554we first constructed NPC cells with stable suppression of
CDK4 protein. We observed that knocking down CDK4
inhibited cell growth and G1 to S phase cell cycle progres-
sion. Our results are similar with these previous reports of
CDK4 function in other tumors. CDK4 mediating miRNA
expression to modulate the pathogenesis of NPC was not
been reported. In this study, we examined the expression
of tumor-suppressive miRNA let-7c by qPCR in NPC cells
after knockdown of CDK4. Interestingly, let-7c expression
was significantly upregulated after suppressing CDK4 ex-
pression which strongly suggested that CDK4 regulated
let-7c expression in NPC. In previous reports, CDK4 was
observed to be a nuclear expressed protein that forms a
complex with CCND1, CDK6, and p21, and modulates
the expression of pRB activating transcription factor E2F1
[27]. In further analyses, predicted binding sites of tran-
scription factor E2F1 were found in the putative let-7c
promoter, suggesting that E2F1 might modulate let-7c
expression. Therefore, we suspected that knocking down
CDK4 stimulated let-7c expression might be attributed
to the suppression of E2F1. Consistent with this expect-
ation, we discovered that knocking down CDK4 elevated
tumor suppressor p21 and inactivated oncocogenic factors
CCND1, CDK6, and E2F1 in NPC cells. Subsequently, weon analysis of overall survival duration
sis Multivariate analysis
95% CI P HR 95% CI
0.660-2.097 0.930 1.027 0.560-1.885
0.760-2.159 0.933 0.977 0.568-1.680
0.319-3.273 0.917 0.940 0.289-3.052
0.495-2.060 0.452 1.340 0.625-2.876
0.598-2.489 0.709 1.171 0.512-2.679




2.467-11.054 0.000 4.527 2.041-10.042
0.920-2.626 0.087 1.671 0.928-3.008
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the expression of let-7c in NPC cells.
Let-7c has been identified as a tumor suppressor in
some tumors [15,16]. However, its roles in NPC have
not been yet reported. In this study, we found that let-7c
was significantly decreased in NPC tissues compared to
nasopharyngeal tissues. Further, we observed that let-7c
inhibited cell growth, migration, and invasion of NPC
cells. These results suggested that let-7c functions as a
potential tumor suppressor in NPC. In a previous study,
let-7c was reported to directly target C-Myc-mediated
CDK4 suppression blocking cell growth in some tumors.
In this investigation, we observed that p15 and p16
[28-31], two tumor suppressors that are upstream regu-
lators of CDK4 [32] were positively modulated by let-7c,
whereas CDK4 and E2F1 were negatively regulated by
let-7c in NPC cells. These results suggested that let-7c
suppressed cell growth through p15/p16/CDK4/E2F1
signaling in NPC. More interestingly, a positive feedback
loop of CDK4-E2F1-let-7c was observed, which was simi-
lar to our previous report for CTGF-C-Jun/C-Myc-miR-
18b in NPC which promoted NPC pathogenesis [13].
Increased expression of CDK4 has been reported in
NPC [12]. However, the correlation of CDK4 expression
with clinical features and prognosis of NPC has not been
documented. In this study, we observed that CDK4 was
mainly coexpressed in the nucleus and cytoplasm in lung
cancer and normal lung tissues. Furthermore, we found
that total protein levels of CDK4 were overexpressed in
NPC tissues compared to normal NP tissues. These results
were analogous to our previous reports in lung cancer
[12], suggesting that CDK4 participates in the pathogen-
esis of NPC.
CDK4 expression patterns had been reported to be
associated with clinical pathology parameters in some
tumors including lung cancer, osteosarcomas, colorectal
cancer, and chondrosarcomas [12,33-35]. In this study,
we observed that overexpressed CDK4 was positively
associated with clinical stage, but not correlated with
patient's age, sex, smoking, or T classification, N classifi-
cation, and M classification in NPC. Further, we ob-
served that the level of CDK4 protein expression was
significantly correlated with the overall survival of NPC
patients. Patients with higher levels of CDK4 expression
had poorer survival rates than those with lower levels of
CDK4 expression. NPC is highly sensitive to radiother-
apy. In this study, we also observed that NPC patients
with the treatment of radiotherapy had markedly better
overall survival rates than those without the treatment
of radiotherapy, which indicated the significance of
radiotherapy for NPC patients. Finally, we found that al-
though CDK expression was not significantly associated
with overall survival of NPC patients according to univari-
ate analyses, it seemed that its overexpression showed atendency as an independent prognostic factor for NPC
patients regardless of its patients' disease status based on
multivariate analyses.
Conclusions
In summary, our study demonstrated that knocking down
CDK4 induced the activation of let-7c by modulating the
p15/p16/CDK4/E2F1 pathway, which in turn suppressed
cell proliferation by controlling p21/CCND1/CDK4/E2F1
signaling. Furthermore, we observed that overexpressed
CDK4 is an unfavorable factor which promotes progres-
sion and poor prognosis of NPC.
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